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Background: Blood Pressure (BP) is not well controlled and factors that predict BP control are not well identified in
Lebanon. Improvement of hypertension management requires an understanding of patients’ characteristics and
factors associated with uncontrolled BP. This national, multicentric, observational prospective study was designed
to determine the predictors of BP control in patients followed up to 6 months.
Methods: I-PREDICT study was conducted on 988 patients with newly diagnosed or uncontrolled hypertension.
Socio-demographic and clinical characteristics were analyzed. The level of agreement between doctors’ perceptions
on BP control status and JNC VII guidelines was analyzed.
Results: The predictor associated with poor BP control was diabetes (OR = 0.17, CI = 0.10–0.28 at month-1; OR = 0.15,
CI = 0.10–0.24 at month-6). The predictors associated with better BP control at month-6 were the early control of BP
at month-1 (OR = 10.39, CI = 6.18–17.47) and combination therapy prescribed at baseline and month-1 (OR = 15.14,
CI = 1.09–208.46, P = 0.04). In the sub-group of diabetes, the predictors that were associated with better BP control at
6 months were following diet at V1 (OR = 2.27, CI = 1.01 to 5.12) and BP control at V2 (OR = 7.34, CT = 3.83 to 14.07).
The predictors that were associated with poor BP control at 6 months were middle economic class (OR = 0.036,
CI = 0.16-0.94) and upper economic class (OR = 0.036; CI = 0.13-0.93).
The rate of BP control was significantly higher at month 6 versus month 1 (67.52% vs 44.08%, P = 0.001). Additional
analysis showed poor agreement between the doctors’ perceptions on BP control status and the guidelines.
Conclusions: Reaching an early BP control and combination therapy were significant predictors of better BP control,
whereas diabetes was a significant predictor of poor BP control. A poor agreement between JNC VII guidelines and
clinical practice was observed. I-PREDICT study identified factors that can be targeted for improving BP control.
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High blood pressure is a major risk factor for cardiovascu-
lar diseases, it is estimated to account for 13% of deaths
worldwide [1]. Deaths from stroke in the Middle East and
North Africa will nearly double by 2030 [2]. Furthermore,
almost three-quarters of people with hypertension (639
million people) live in developing countries with limited
health resources and where people have a very low aware-
ness of hypertension and poor blood pressure control [1,3].* Correspondence: sm104@aub.edu.lb
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unless otherwise stated.Within the past few years, the prevalence of hypertension
is increasing and is predicted to grow by more than 500
million by 2025 [4,5].
In developing countries including Lebanon, the high
prevalence of hypertension and poor hypertension control
are important factors in the rising epidemic of cardiovas-
cular disease. In Lebanon, around 39% prevalence of
hypertension is reported among the general population
[6]. Lebanon has a higher prevalence of hypertension
compared to Tunisia (30, 6%) [7], Greece (30, 5%) [8],
Turkey (31.8%) [9] and Jordan (15%) [10]. Among patients
with coronary artery disease studied in The Lebanese
Interventional Coronary Registry (LICOR) in 2011, thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Mallat et al. BMC Public Health 2014, 14:1142 Page 2 of 9
http://www.biomedcentral.com/1471-2458/14/1142most common reported cardiovascular risk factor was
high BP reaching a prevalence of around 62.5% [11].
LICOR is in a national registry of more than 47 092 inter-
ventional events by 2011 (cardiac catheterization and
percutaneous coronary intervention) from more than 40
sites across all Lebanon. These results highlight the urgent
need for intervention to prevent, treat and control hyper-
tension [12].
The main challenge about hypertension is the number of
patients who are not in control of their BP. If left uncon-
trolled, hypertension can lead to coronary artery disease,
an enlargement of the heart and eventually heart failure
[13]. The number of uncontrolled hypertensive patients
also varies by countries [14]. Such that, in USA, analysis of
data from the National Health and Nutrition Examination
Survey (NHANES) 2003–2010 showed that among pa-
tients with hypertension in the general population, an esti-
mated 35.8 million (53.5%) did not have their hypertension
controlled at the 140/90 mm Hg threshold [15]. Mean-
while, within Europe, rates of BP control among hyperten-
sive treated cases were 40%, 30%, 28%, 19% and 21%
respectively in England, Germany, Italy, Spain and Sweden
at the 140/90 mm Hg threshold from 1997 to 1990 [14].
Similarly, hypertension was not controlled to the recom-
mended levels of BP in about one-half (50.4%) of patients
during the period of June to December 2006 in Jordan.
Globally, the low BP control rates have been difficult to
explain, given the number of apparently well-tolerated
medications available for the management of hyperten-
sion. Factors related to access to care, medical practice
patterns, patient education, poor compliance to prescribed
treatment and patient cardio-metabolic profile have all
been proposed as barriers to BP control [16-18]. However,
BP is also determined by other factors, including age,
severity of disease, health habits, and early control and co-
morbidities [17,18].
Further identification of patients at risk of poor control
can lead to targeted interventions to improve management
of hypertension. Besides, in order to improve the BP con-
trol rate in the population with hypertension, a more
complete understanding of the predictors of BP control is
essential.
The following study (I-PREDICT) is a national, multi-
centric, observational, prospective cohort survey which
aimed to identify the predictors of BP control in hyperten-
sive Lebanese patients followed up to 6 months. The
secondary objectives were to identify the predictors after 1
month of follow-up and to evaluate the number of hyperten-
sive patients who are and are not at goal at months 1 and 6.
Subjects and methods
Study population
From April 2010 to November 2010, a national, multi-
centric, observational, prospective cohort survey wasconducted on 1079 patients, with newly diagnosed or
uncontrolled hypertension on previous medications, in
107 centers all over Lebanon. Participating centers were
either private clinics or hospitals based outpatient clinics.
Institutional review board (Makassed General Hospital
and Rafic Hariri University Hospital) approved the study
protocol and the study was performed in compliance
with Good Clinical Practices.
Methods
One hundred seven (107) randomly selected physicians
from across Lebanon were invited to participate in the
study. Their number was determined based on the sample
size and the recruitment period. Each physician was
requested to enroll the first 10 eligible patients who met
the eligibility criteria and gave written informed consent.
Eligible participants for this survey were men and women
18 years old or above with newly diagnosed hypertension
or uncontrolled hypertension on medications. Exclusion
criteria included pregnancy, lactation, secondary hyperten-
sion or participation in another study.
Hypertension was considered uncontrolled if BP was
more than 140/90 mm Hg in hypertensive patients and
more than 130/80 mm Hg in hypertensive patients with
diabetes and chronic kidney disease. Those thresholds
were based on the latest report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC VII) and the
guidelines for the management of arterial hypertension
of the European Society of Hypertension [19,20].
Data collection
Case report forms in English were used to collect patients’
data, from the physicians, over 6 months follow-up after
enrolment in the study. Data were collected at baseline
and during two follow-up visits when performed by the
patients. The information included the following: dates of
visits, verification of the eligibility criteria, systolic and
diastolic blood pressures, whether the patient is newly
diagnosed with hypertension or not, co-morbidities (dia-
betes, atherosclerotic cardiovascular diseases, dyslipidemia
and chronic kidney disease), lifestyle (diet, exercise and
smoking), medical treatment for hypertension and num-
ber of prescribed antihypertensive medication. The survey
also obtained data on patient’s gender, weight, height,
waist circumference, educational level, marital and socio-
economic status assessed by the investigator, home blood
pressure monitor (possession of any validated sphygmo-
manometer at home) and knowledge of the patient of his
target blood pressure.
This study is purely observational of real-life practices,
therefore no specific method of evaluation was defined.
Physician’s therapeutic decisions and patients’ assessment
were based on usual real-life practices.
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Although, we do realize that using an automatic device is
an objective method of BP assessment but in line with the
study design, we didn’t impose any specific tool in order
not to introduce any bias in the “real-life” assessment.
Reported diabetes was based on a history of diabetes
mellitus as diagnosed by a physician or other health pro-
fessional, or if they were receiving insulin or oral diabetic
medications. Diabetes type 1 and 2 were analyzed to-
gether. Educational level was defined as the highest level
of education completed. Based on the physician’s assess-
ment of patients’ living conditions and satisfaction of
needs, as done in real-life, the socio-economic status was
classified as being low, middle or high. Waist circumfer-
ence was measured to the nearest centimeter using non-
stretchable tailors measuring tape at the midway between
the lower rib margin and the iliac crest. The patient was
asked to breathe normally and the reading was taken at the
end of the light exhale. Height and weight were measured
in patients wearing light indoor clothes and no shoes.
Answers for these two parameters were used to calculate
the body mass index (BMI) of each patient as weight (in
kilograms, kg) divided by height (in meters, m) squared
(kg/m2). Normal weight was defined as having a BMI of
18.5–24.9 kg/m2, overweight of 25.0–29.9 kg/m2 and obes-
ity as BMI ≥ 30 kg/m2, as defined by the World Health
Organization (WHO) classification of 2004 [21].Table 1 Interpretation of kappa according to Landis and
Kosh [22]
Kappa Agreement





0.81–0.99 Almost perfect agreementStatistical analysis
Sample descriptive statistics, including frequencies,
percentages, means, standard deviations and ranges, were
calculated to summarize the socio-demographic and clin-
ical characteristics of the study cohort at baseline. Con-
tinuous variables were expressed as means and standard
deviations and categorical variables as percentages.
A multivariate analysis using logistic regression models
was conducted to identify independent predictors of BP
control after 1 month and 6 months of follow-up. The ini-
tial full models with BP control as the outcome variable
included the following set of covariates/predictor vari-
ables: diabetes, education level, following diet, myocardial
infarction, dyslipidemia, atrial fibrillation, chronic kidney
disease, smoker, exercising, newly diagnosed, combination
therapy at baseline, months 1 and 6, and BP controlled at
months 1 and 6. The risks were reported as odds ratios
(OR) with corresponding 95% confidence intervals (CI). A
two-tailed P value <0.05 was considered statistically
significant.
Besides, the statistical analysis evaluated the number
of hypertensive patients who were or not at goal at
months 1 and 6. Chi-square test was used for categorical
outcomes (controlled/uncontrolled BP) using a two-tailed
P value <0.05 for statistical significance.Importantly, additional analysis was performed to assess
the level of agreement between doctors’ perceptions on
blood pressure control status and JNC VII guidelines
Indeed, Physicians were asked about the categorization of
their patients’ blood pressure status. According to JNC7
Guidelines, patients’ blood pressure control status was
identified separately. Using SPSS, Kappa agreement
according to Landis and Kosh’s classification, which is
universally accepted (Table 1) [22] was calculated between
the two variables. The statistical analysis was carried out
using STATA and SPSS softwares for Windows Release
(Stata Corp, College Station, Texas, USA, version 11 and
SPSS Inc., Chicago, USA, version 17.0).
Results
Recruitment
A total of 1079 patients in 107 centers all over Lebanon
were recruited in this survey of whom 988 were eligible
for the statistical analysis (Figure 1).
Socio-demographic characteristics of the patients at baseline
Overall, 55% (N = 543) of the patients were men and
45% (N = 445) were women. The percentages of patients
with newly diagnosed hypertension versus known to be
hypertensive on medications were respectively 51.3%
and 48.7%.
At baseline, out of 988 patients, the mean systolic BP
was 166.74 ± 37.74 mm Hg, and the mean diastolic BP
was 94.01 ± 9.18 mm Hg. The mean BMI was 28.75 ± 4.08
Kg/m2. The average waist circumference was 98.42 ±
16.02 cm.
Table 2 presents basic socio-demographic information
of the cohort study all over Lebanon.
Sub-group analysis of the diabetic population
There is a significant difference in the geographic distribu-
tion of diabetic versus non-diabetic patients such that
patients in Beirut are more likely to be non-diabetic
(p = 0.002). Additionally there is a significant difference in
the educational levels of diabetic patients versus non-
diabetic patients where non-diabetic patients are more
likely to have higher educational levels (p = 0.022). Details
are shown in Table 3.
N1: eligible patients who completed visit at month 1
N2: eligible patients for analysis
Figure 1 Patients’ flowchart.
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Regarding co-morbidities, 41.27% were smokers. Dyslipid-
emia and diabetes were more frequently present with per-
centages of 57.39% and 39.27% respectively. Co-morbidities
of patients at baseline are detailed in Table 4.
There is no significant difference between diabetic
versus non-diabetic patients; such that the mean systolic
and diastolic blood pressure, weight and waist circum-
ference were comparable between the two subgroups.Distribution of anti-hypertensive medications
At baseline, the majority of patients received a combin-
ation therapy (71.3% vs. 28.7% on monotherapy) and this
observation was maintained same across visits. Details on
distribution of anti-hypertensive medication is detailed in
Table 5.Predictors of BP control
In multivariate analysis, a number of factors were found
to be associated with BP control in hypertensive patients
at the follow-up visits (months 1 and 6) (Table 6).The predictor that was associated with poor BP con-
trol at the two follow-up visits was diabetes (OR = 0.17,
CI = 0.10 to 0.28 at month 1; OR = 0.15, CI = 0.10 to 0.24
at month 6).
The predictors that were associated with better BP con-
trol at month 6 were the early control of blood pressure at
month 1 (OR = 10.39, CI = 6.18 to 17.47) and combination
therapy at baseline and month1 (OR = 15.14, CI = 1.09 to
208.46, P = 0.04). Patients treated with combination therapy
at baseline and month 1 had a better BP control at month
6 compared to those being treated with monotherapy at
baseline.
No significant association with blood pressure control
was found for educational level, following diet, exercis-
ing, smoking, dyslipidemia, myocardial infarction, atrial
fibrillation, chronic kidney disease and new diagnosis of
hypertension.
In the sub-group of diabetes, the predictors that were as-
sociated with better BP control at 6 months were following
diet at V1 (OR = 2.27, CI = 1.01 to 5.12) and BP control at
V2 (OR = 7.34, CT = 3.83 to 14.07). The predictors that
were associated with poor BP control at 6 months were
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upper economic class (OR = 0.036; CI = 0.13-0.93).
Rate of BP control
The percentages of patients who had controlled blood











Highest completed education Illiterate
Primary school
Secondary school
hHigher educationand 67.52%. The rate of BP control was significantly
higher at month 6 versus month 1 (P = 0.00).
Level of agreement between doctors’ perceptions on
blood pressure status and JNC VII guidelines
The measurement of agreement between doctors’ percep-
tions on BP control and JNC VII guidelines showed a poor
agreement between the two parameters at the follow-up
visit at month 1 (kappa < 0) whereas it was fair at the
follow-up visit at month 6 (kappa = 0.26) according to
Landis and Koch characterization’s [22].
Discussion
I-PREDICT survey is the first study that attempts to
identify the predictors of BP control in the Lebanese
population nationwide. It identifies diabetes as a predictor
of poor BP control in subjects with hypertension. This is
consistent with findings from previous studies that
showed a higher predilection for uncontrolled BP in dia-
betic patients [17,23-26]. Despite the known fact that the
prevalence of hypertension in adults with diabetes is very
high [18,27-29], results showed that diabetic patients with
hypertension are poorly controlled as compared to non-
diabetic patients [18,27]. These findings highlight a dis-
tinct risk in the diabetic population since diabetes is
associated with high cardiovascular mortality. Indeed, the
Framingham study has revealed that much of this risk is
due to coexisting hypertension [30]. Both macrovascular
and microvascular complications are increased in hyper-
tensive diabetic patients when compared to normotensive
diabetic patients [26]. In addition, hypertension was the
strongest determinant of cardiovascular outcomes in
diabetic patients [30]. Since the diabetic population repre-
sents a significant percentage of the general population inween diabetic and non-diabetic populations















Table 4 Co-morbidities of patients at baseline





Left ventricular hypertrophy 26.31%
Myocardial infarction 12.22%
Chronic kidney disease 4.62%
Congestive Heart failure 4.12%
Atrial fibrillation 3.90%
Stroke 3.49%
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[32]), analysis of the predictors of BP control in this group
would potentially help improve cardiovascular outcomes
and mortality.
Moreover, early control of blood pressure is known to
improve BP to a significant extent over time [18,33,34]. In
fact, the multivariate analysis in our study also showed
that early control of BP was a significant predictor for a
better BP control at a later follow-up.
This study also showed that combination therapy had a
statistical advantage in terms of BP control (OR = 15.14,
CI = 1.09 to 208.46, P = 0.04). Patients who stayed on
combination therapy by the time of the third follow-up
visit at month 6 had a better BP control when they were
already taking a combination therapy at baseline and
month 1 as compared to those being treated with mono-
therapy at baseline. Several studies have shown that com-
bination therapy may improve control rates of BP [35-37].
In addition, Egan et al. reported that initial antihyperten-
sive combination therapy produced more rapid BP control
than initial monotherapy in clinical trials [36].
The results of the study show also that the study popula-
tion tends to be overweight as the mean BMI was 28.75 ±
4.08 kg/m2. Also, almost near 4 in 10 patients were
smokers. These findings display the importance of pressing
the need for lifestyle modification in hypertensive patients
in Lebanon, since smoking abstinence and weight loss have
shown to be key players in BP control [20].Table 5 Distribution of anti-hypertensive medication per visit







ARB = Angiotensin Receptor Blocker; ACEI = Angiotensin Converting Enzyme; InhibitFollow-up results showed a significantly larger popula-
tion reaching control at 6 month (67.52%) as compared
to month 1 (44.08%). The overall BP control rate, after 6
months, in this cohort, is higher than international studies’
rates [15,38,39]. Such that, 50% of the NHANES study
population reached control after 1 year follow-up [39].
Similarly, 40% of the treated hypertensive patients
achieved their BP target in England after 1 year follow-
up [14,40]. Even though I-PREDICT design is different
from NHANES and the European surveys’ one, early
follow-up of BP may have contributed to better inter-
vention thus leading to high rate of BP control in our
population study.
BP outcomes according to JNC VII guidelines stratifica-
tion was used throughout the analysis. The results of
kappa statistics regarding the level of agreement between
physicians’ perception and guidelines showed poor to fair
agreement according to Landis and Koch’s classification.
Such level of agreement reflects a gap between clinical
practice and international guidelines. Factors related to
insufficient access to guidelines at the point of care, insuf-
ficient information technology systems, especially for the
small or solo practices, in addition to the culture, beliefs
and habits of physicians and guidelines development have
all been proposed as barriers to physician adherence to
guidelines [41]. In fact, physicians tend to rely on their
own judgment and personal experience to determine
whether or not they are taking the right initiative for
patients. Moreover, guidelines themselves often lack suffi-
cient flexibility and relevance to clinical practice. Many
guidelines do not reflect the complexity and context in
which real clinical decisions must be made [41].
Limitations
We acknowledge several limitations of the study. First, a
sampling bias might have occurred at two levels: physi-
cians’ selection and patients’ selection, which may affect
the generalization of our results to the whole Lebanese
population. Second, assessment of BP control was based
on the measurement of diastolic and systolic BP at the
clinic visit. People with hypertension often experience a
spike in BP when the reading is taken in a physician’s







or; CCB = Calcium Channel Blocker.
Table 6 Predictors associated with blood pressure control
in multivariate analysis (follow-up visit at month 6)
Covariates OR 95% CI P value
Diabetes 0.15 0.10–0.24 0.00*
BP control at month 1 10.39 6.18-17.47 0.00*
Combination therapy at
baseline and month 1
15.14 1.09–208.46 0.04*
Educational level
Primary school 1.07 0.29–4.00 0.92
Secondary school 0.73 0.19–2.70 0.63
Higher education 0.81 0.19–3.31 0.77
Following diet 1.30 0.68–2.42 0.42
Myocardial infarction 0.71 0.40–1.26 0.24
Dyslipidemia 1.34 0.87–2.06 0.17
Atrial fibrillation 0.39 0.14–1.09 0.07
Chronic kidney disease 0.62 0.25–1.55 0.30
Smoker 1.07 0.72–1.59 0.72
Follow exercise 1.01 0.64–1.61 0.95
Newly diagnosed 0.87 0.57–1.34 0.54
Sub-group of diabetes
Following diet at V1 2.27 1.01-5.12 0.047*
BP controlled at V2 7.34 3.83-14.07 0.000*
Middle economic class 0.39 0.16-0.94 0.036*
Upper middle class 0.30 0.13-0.93 0.036*
CI = Confidence interval; OR = Odds ratio.
*Significant.
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control. To account for this “white coat effect”,
researchers found significantly greater accuracy when
several BP readings were combined from measurements
taken at home or in the doctor’s office [42-44].
Finally, some studies have shown that advancing age is
the foremost reported predictor factor of poor BP control
[17,24,45,46]. However, we are unable to retrieve this data
for the time being.
Conclusion
I-PREDICT survey has the merit to be the first national
study involving a large number of centers across a develop-
ing country. The results of this survey are informative as
they suggest early control of BP and combination therapy
as predictive factors of better BP control, and diabetes type
1 and 2 as a predictor of poor BP control in the population.
Patients with these characteristics may represent important
factors to target for better control in clinical practice.
Clearly, our study may contribute to closing the knowledge
gap on the predictors for BP control in Lebanon. Another
positive finding is that rate of BP control in our cohort was
high compared to international studies. Nonetheless,
several approaches are to be applied in order to improvephysician adherence to clinical practice guidelines. Phy-
sicians can play a key role in implementing any com-
prehensive, national program to improve hypertension
management in Lebanon, but their assessment should
be more objective and based on guided criteria in order
to avoid subjectivity and medical inertia [47,48].
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